DUBLIN–(BUSINESS WIRE)–The “Krabbe Disease Treatment – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s providing.
Amid the COVID-19 disaster, the worldwide marketplace for Krabbe Disease Treatment estimated at US$833.8 Million within the 12 months 2020, is projected to achieve a revised dimension of US$1.2 Billion by 2027, rising at a CAGR of 5.6% over the evaluation interval 2020-2027.
Anticoagulants, one of many segments analyzed within the report, is projected to file a 5.4% CAGR and attain US$503 Million by the top of the evaluation interval. After an early evaluation of the enterprise implications of the pandemic and its induced financial disaster, development within the Muscle Relaxants section is readjusted to a revised 5.1% CAGR for the subsequent 7-year interval.
The U.S. Market is Estimated at $245.8 Million, While China is Forecast to Grow at 5.2% CAGR
The Krabbe Disease Treatment market within the U.S. is estimated at US$245.8 Million within the 12 months 2020. China, the world’s second largest financial system, is forecast to achieve a projected market dimension of US$214.8 Million by the 12 months 2027 trailing a CAGR of 5.2% over the evaluation interval 2020 to 2027. Among the opposite noteworthy geographic markets are Japan and Canada, every forecast to develop at 5.3% and 4.4% respectively over the 2020-2027 interval. Within Europe, Germany is forecast to develop at roughly 4.6% CAGR.
HSCT Segment to Record 6.5% CAGR
In the worldwide HSCT section, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this section. These regional markets accounting for a mixed market dimension of US$135.1 Million within the 12 months 2020 will attain a projected dimension of US$210.6 Million by the shut of the evaluation interval. China will stay among the many quickest rising on this cluster of regional markets. Led by nations resembling Australia, India, and South Korea, the market in Asia-Pacific is forecast to achieve US$140.3 Million by the 12 months 2027.
Select Competitors (Total 42 Featured):
- Abbott Laboratories
- CENETOGENE N.V.
- Johnson & Johnson
- Novartis AG
- Sanofi-Aventis SA
- Teva Pharmaceutical Industries Ltd.
- UCB Pharmaceuticals
Key Topics Covered:
II. EXECUTIVE SUMMARY
III. MARKET ANALYSIS
- Total Companies Profiled: 42
For extra details about this report go to https://www.researchandmarkets.com/r/a8iiqi